



Shmuel Einav, Ph.D. Joins The Channel Group, LLC and Its Affiliate BioMed Transition Partners as an Advisory Partner

May 17, 2011, New York

The Channel Group, LLC announced today that Shmuel Einav, Ph.D. has joined The Channel Group and its affiliate, BioMed Transition Partners, as an Advisory Partner. Dr. Einav is well-known for his seminal contributions to the field of biomedical engineering and his studies on the cardiovascular circulatory system. He is currently Professor of Biomedical Engineering and Director, Medical Technologies Division, Center of Excellence for Wireless and Information Technologies at Stony Brook University. As Director of Ramot - University Authority for Applied Research and Industrial Development Ltd., the technology transfer organization of Tel Aviv University, he initiated more than 15 start-up companies and managed \$30M in assets and 90 employees.

Dr. Einav also was a founder or advisor to several medical device companies, including: NiCast, Ltd., a developer and marketer of bio-impedance based cardiac monitors; Florence Medical Ltd., a stent and cardiovascular diagnostic technology company; IntelliDX Inc. (formerly Glucon Medical Ltd.), a developer and marketer of a blood glucose testing system for monitoring hospital patients who have abnormally elevated sugar levels; and, Venter Technologies Ltd., a developer of trans-catheter heart valve technologies that was acquired by Medtronic, Inc. for \$325 million in 2009.

He also was a member of the advisory board of several venture capital funds, including Veritas Venture Partners, InnoMed Fund of Jerusalem Global Ventures, and Ramot Medical Fund. Dr. Einav is Emeritus Professor and Incumbent of the Herbert Berman Chair for Vascular Bioengineering at Tel Aviv University. He earned a B.Sc. and an M.Sc. in Mechanical and Nuclear Engineering from the Technion (Haifa), and a Ph.D. in Biomechanical Engineering from Stony Brook University.

"Shmuel's experience in a wide range of medtech technologies and companies expands our expertise and adds another dimension to our team," commented Allan R. Goldberg, Ph.D., a Managing Partner of The Channel Group.

"The Channel Group and its affiliate, BioMed Transition Partners, have been built by accomplished operating executives who have solid track records in the biotechnology/biomedical industries. Together we anticipate creating several exciting new companies and helping other companies achieve their potential," said Dr. Einav.

About The Channel Group

The Channel Group is a New York-based venture investment, development, and management company that focuses on the creation of companies in the life sciences and biomedical industries. Its Partners include Robert J. Beckman, Philip N. Sussman, and Vijay Aggarwal, Ph.D., in addition to Dr. Goldberg. See www.thechannelgroup.com for further information.

BioMed Transition Partners

BioMed Transition Partners provides advisory and management support to biomedical companies that are seeking to effect strategic change, transactional opportunities, or require operating management support. See www.biomedtransitionpartners.com for further information.

Contact

The Channel Group, Sherry Stone, 212 330-8076, info@thechannelgroup.com
